Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis

Program death-1 inhibitors, a class of immune-checkpoint inhibitors, are now the standard of care in a variety of cancer settings, including cutaneous malignancies, such as melanomas, Merkel cell, and cutaneous squamous cell carcinomas (cSCCs). The clinical trials that led to the approval of the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Grace de Lima, Stacy, Hyrcza, Martin D., Monzon, Jose Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984937/
https://www.ncbi.nlm.nih.gov/pubmed/36880029
http://dx.doi.org/10.1159/000528414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984937/
https://www.ncbi.nlm.nih.gov/pubmed/36880029
http://dx.doi.org/10.1159/000528414

Ejemplares similares